Depot medroxyprogesterone acetate (DMPA) for subcutaneous administration (DMPA‑SC) inhibits the secretion of gonadotrophins which, in turn, prevents follicular maturation and ovulation. The primary mechanism of ovulation suppression also results in endometrial thinning, and these actions produce its contraceptive effect (see the Sayana Press summary of product characteristics).
DMPA‑SC is indicated for use as long-term female contraception. Each subcutaneous injection provides contraception for at least 13 weeks (±1 week). However, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to 1 year.
The dose of DMPA‑SC given in the Sayana Press summary of product characteristics is 104 mg administered by subcutaneous injection within the first 5 days of the menstrual cycle or post-partum in women who are not breastfeeding (if the woman is breastfeeding, the injection should not be given before 6 weeks post-partum).
The injection should be repeated at 13‑week intervals. If given within 7 days after the 13‑week interval, no additional contraception is needed. If the injection is given more than 7 days after the 13‑week interval, pregnancy must be excluded before the injection is repeated and additional contraceptive precautions must be taken.
The cost of each prefilled injector containing 104 mg/0.65 ml suspension is £6.90 (excluding VAT: MIMs December 2013).